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Introduction: Morphine is a common opiate administered for medicinal purpose to
suppress pain. Many opiates, contribute to the common addiction problem that may arise
from these preoperative drugs. Patients may become tolerant to morphine through repeated
use, requiring a higher dosage to produce the same effect. Mambalgin-1 peptide, a protein
component of Black Mamba snake venom poses a possible solution to morphine addiction.
Since extraction is inefficient the objective is to use the Escherichia coli (E.coli) plasmid,
PSB1C3, Mambalgin-1 cDNA, along with specific ribosome binding site (RBS) sequences
and primers for polymerase chain reaction (PCR) to express the protein without milking
snakes.
Purpose: This project is a part of the International Genetically Engineered Machine (iGEM)
competition, which consists of the standardization of DNA parts and collaboration with other
universities. In our collaboration with the G.A Tech iGEM team, synthetic biology techniques
were applied to induce the expression of Mambalgin in E. coli. Using the designed
prokaryotic promoter along with RBS and PCR primers to optimize the expression of
Mambalgin, eukaryotic peptide, in the prokaryotic chassis to obtain a high yield of pure
Mambalgin-1.
Method: Standard techniques were used including, PCR for amplification of Mambalgin
cDNA, gel electrophoresis to verify gene of interest, ligation was performed to incorporate
Mambalgin into standardized PSB1C3 plasmid. This vector was transformed into E. coli in
order to yield efficient expression.
Results: Initial testing and sequencing (GA Tech) confirm the presence of RBS, and
Mambalgin cDNA. Sequencing will confirm the presence of Mambalgin cDNA in PSB1C3
and western blot will confirm the protein by using antibodies that are specific to the
Mambalgin peptide.
Conclusion: Future direction of this project is to test addictive, analgesic and
immunological side effects using animal models. This testing will provide understanding of
many health factors associated with Mambalgin-1 protein. This protein can be introduced to
the pharmaceutical industry as a morphine replacement. Furthermore, many health care
benefits can come from mass production of this protein including a decline in the problem of
opiate addiction.

